



NeuroScientific
BIOPHARMACEUTICALS

28 April 2021

ASX Announcement

Manufacturing Update

Perth Australia, 28 April 2021: Neuroscientific Biopharmaceuticals Limited (**ASX: NSB**) (**NeuroScientific** or the **Company**) is pleased to announce that the major manufacturing milestone of process scale-up for large batch production of the Company's lead drug candidate, called EmtinB, has been successfully completed and resulted in actual yields being increased by more than 80% over the expected manufacturing yields. Manufacturing of clinical-grade EmtinB is underway in preparation for upcoming clinical studies.

Having previously completed the complex process optimisation stage of manufacturing in 2020, the next critical manufacturing milestone involved scale-up studies to verify the chemistry processes work for large-scale production of clinical-grade EmtinB. Efficiencies incorporated during process optimisation resulted in more than 80% increase in yields of EmtinB drug substance during the scale-up studies. This additional EmtinB drug substance will be used to accelerate several studies in the Company's preclinical neurology safety and toxicity program.

Managing Director and CEO, Matt Liddelow commented, "The Company has taken another major step in progressing EmtinB into clinical development, and as a result of methodical planning and working closely with our manufacturing partners, our manufacturing program is hitting its key objectives with increased efficiency. It should also be noted that well-planned scale-up studies also set the foundation for effective commercial-scale production of drug API (active pharmaceutical ingredient) in the future."

Production of clinical-grade EmtinB, manufactured to Good Manufacturing Practice (GMP) standards, is currently being undertaken by leading Swiss contract manufacturing company Bachem AG and further updates will be provided in the near future. Non-GMP grade EmtinB, which is used for preclinical studies, is currently manufactured by Bachem AG and Mitsubishi / Peptistar.

About NeuroScientific Biopharmaceuticals Ltd

NeuroScientific Biopharmaceuticals Limited (ASX:NSB) is a company developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The company's product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer's disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn) which have demonstrated similar therapeutic potential as EmtinB. For more information, please visit www.neuroscientific.com

END

Announcement authorised by the Board of Directors of NeuroScientific Biopharmaceuticals

Contacts

Matthew Liddelow
CEO and Managing Director
ml@neuroscientific.com
+61 8 6382 1805

Brian Leedman
Non-executive Chairman
bl@neuroscientific.com
+61 412 281 780